Activation of OCT4 enhances ex vivo expansion of human cord blood hematopoietic stem and progenitor cells by regulating HOXB4 expression by Huang, Xinxin et al.
Activation of OCT4 enhances ex vivo expansion of human cord 
blood hematopoietic stem and progenitor cells by regulating 
HOXB4 expression
Xinxin Huang1, Man-Ryul Lee1,2, Scott Cooper1, Giao Hangoc1, Ki-Sung Hong3, Hyung-Min 
Chung3, and Hal E. Broxmeyer1,4
1Department of Microbiology and Immunology, Indiana University School of Medicine, 
Indianapolis, Indiana, USA
2Soonchunhyang Institute of Medi-bio Science, Chungcheongnam-do, Korea
3Konkuk University School of Medicine, Seoul, Korea
Abstract
Although hematopoietic stem cells (HSC) are the best-characterized and the most clinically used 
adult stem cells, efforts are still needed to understand how to best ex vivo expand these cells. Here 
we present our unexpected finding that OCT4 is involved in the enhancement of cytokine-induced 
expansion capabilities of human cord blood (CB) HSC. Activation of OCT4 by OAC1 in CB 
CD34+ cells enhanced ex vivo expansion of HSC, as determined by a rigorously defined set of 
markers for human HSC, and in vivo short-term and long-term repopulating ability in NSG mice. 
Limiting dilution analysis revealed that OAC1 treatment resulted in 3.5 fold increase in the 
number of SCID Repopulating Cells (SRC) compared with that in Day 0 uncultured CD34+ cells 
and 6.3 fold increase compared with that in cells treated with control vehicle. Hematopoietic 
progenitor cells, as assessed by in vitro colony formation, were also enhanced. Furthermore, we 
showed that OAC1 treatment led to OCT4-mediated upregulation of HOXB4. Consistently, 
siRNA-mediated knockdown of HOXB4 expression suppressed effects of OAC1 on ex vivo 
expansion of HSC. Our study has identified the OCT4-HOXB4 axis in ex vivo expansion of 
human CB HSC.
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Introduction
Hematopoietic stem cells (HSC) are responsible for maintaining and replenishing all blood 
cell lineages during a lifetime. Allogeneic hematopoietic cell transplantation (HCT) is well 
established as a clinical means to treat patients with hematologic disorders and cancer. 
Human cord blood is an alternative source of HSC for transplantation1–3; the advantages of 
using CB as a hematopoietic source for HCT are: easy accessibility of banked HLA-typed 
CB and, decreased graft-versus-host disease. However, numbers of nucleated cells retrieved, 
as well as limited numbers of HSC/progenitor (HPC) cells present, during collection may be 
problematic for treatment of adult patients with single CB HCT. One means to address the 
problem of limiting numbers of HSC/HPC is to ex vivo expand these cells for potential 
clinical use. While progress has been made in this endeavor1, 4, 5, there is still a clinically 
relevant need for additional means to ex vivo expand human HSC and HPC.
The POU domain family transcriptional factor Octamer binding protein 4 (OCT4) is well 
defined as a master regulator for maintenance of totipotency and pluripotency6. In 
embryonic stem cells, OCT4, SOX2 and NANOG form a regulatory circuitry to orchestrate 
self-renewal and suppress differentiation7. In vivo expression of OCT4 and three other 
transcriptional factors enable reprogramming of somatic cells to induced pluripotent stem 
cells8. Surprisingly, ectopic expression of OCT4, together with cytokine treatment, allowed 
generation of human hematopoietic progenitor cells from fibroblasts, suggesting an 
unexpected role of OCT4 during hematopoietic fate transition9. Recently, a small molecule 
library screen identified Oct4-activating compound 1 (OAC1) as a reagent to increase the 
expression of the endogenous Oct4. OAC1 facilitated the reprogramming of cells by 
enhancing efficiency and shortening the reprogramming time10. Additionally, Oct4 gene 
expression has been reported in a variety of adult stem cells, including breast stem cells, 
pancreatic stem cells, liver stem cells, mesenchymal stem cells and HSC suggesting that 
OCT4 might also function in somatic stem cells11–13. However, the functions of OCT4 in 
somatic stem cells, especially in HSC are largely unknown.
In this study we hypothesized that OCT4 is involved in HSC function and expansion, and 
thus we evaluated the effects of OAC1 on ex vivo culture of CB CD34+ cells in the presence 
of a cocktail of cytokines known to enhance ex vivo expansion of human HSCs. We found 
that CB CD34+ cells treated with OAC1 showed a significant increase above that of this 
cytokine cocktail in the numbers of rigorously defined HSC by phenotype and in vivo 
repopulating capacity in NSG mice, and in numbers of multipotential, erythroid and 
granulocyte macrophage progenitors as determined by colony assays. We identified HOXB4 
as a crucial downstream target of OCT4 and showed that OCT4-HOXB4 axis was essential 
for OAC1-mediated HSC expansion. We did not detect leukemic transformation of engrafted 
cells within the time frame of our experimental observations nor did the cells form teratomas 
in mice. Our data show, for the first time, a functional link between OCT4 expression and 
HSC function, and suggest the potential clinical application of using OAC1, or next 
generation OCT4 activators, to ex vivo expand human HSC.
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Materials and Methods
Mice
All experimental procedures with mice were approved by The Institutional Animal Care and 
Use Committee of the Indiana University School of Medicine. NSG (NOD.Cg-
PrkdcscidIl2rgtm1Wjl/Sz; 8–10 weeks old) mice were obtained from an on-site core breeding 
colony supported at our NIDDK Center of Excellence in Molecular Hematology and the 
NCI-designated Indiana University Simon Cancer Center.
In vitro cell cultures
Normal human cord blood was provided by CordUse, a cord blood banking company. 
Mononuclear cells were isolated by density gradient centrifugation over Ficoll-Paque Plus 
(GE Healthcare). CD34+ cells were obtained by immunomagnetic selection (Miltenyi 
Biotec, Auburn, CA, USA) over two sequential columns. This yields 90–98% purity of 
CD34+ cells. CD34+ cells were then cultured in RPMI-1640 medium containing 10% FBS, 
100 ng/mL stem cell factor (SCF), thrombopoietin (TPO), Fms-like tyrosine kinase 3 ligand 
(Flt3L), in the presence of 500nM OAC1 (Xcessbio, San Diego, CA, USA) or with a vehicle 
control (DMSO). For lentiviral vector transduction, CB CD34+ cells were transduced with 
lentiviral vector pCSC-GW and pCSC-OCT4 (OCT4 cDNA was cloned into AgeI site in 
pCSC-GW plasmid) as previous described14, transduced CD34+ cells were cultured for 4 
days before flow analysis.
Flow cytometry and antibodies
Cells were stained at 4°C for 30 minutes with the following antibodies: Lineage cocktail 
(Lin)-FITC, CD34-APC (581), CD38-PE (HIT2), CD45RA-PECF594 (HI100), CD90-
PEcy7 (5E10), and CD49f-PerCPcy5.5 (GoH3) for phenotypic analysis of HSC and HPC; 
CD3-FITC (UCHT1), CD19-PE (HIB19), CD33-FITC (WM53), CD45-APC (HI30) were 
used for in vivo transplantation. All the above antibodies were purchased from BD 
Bioscience. For intracellular staining, CD34+ cells were fixed, permeabilized and stained 
with OCT4 (C-10, Santa Cruz), SOX2 (57CT23.3.4, Abcam), NANOG (H-155, Santa Cruz) 
or HOXB4 (EP1919Y, Abcam) primary antibodies. Cells were washed and then stained with 
FITC-conjugated secondary antibody for 30 minutes on ice, light protected. Flow analysis 
was performed with a BD Bioscience LSR II and FlowJo software. The negative portion was 
determined by using relevant isotype antibody controls.
In vitro colony-forming unit (CFU) assay
CB CD34+ cells were seeded in triplicate in 1.0 mL methylcellulose culture medium 
supplement with 30% FBS, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol, and 
recombinant human cytokines: 1 U/mL erythropoietin, 50 ng/mL SCF, 10 ng/mL 
interleukin-3 (IL-3), and 10 ng/mL granulocyte-macrophage colony-stimulating factor (GM-
CSF). The number of colonies was scored at Day 14 with an inverted microscope. All cell 
cultures were incubated in a 5%O2/5%CO2 humidified chamber.
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In vivo transplantation
Transplantation of human cells into NSG mice was done as described previously14, 15. 
Briefly, 8–10 week old NSG mice were sublethally irradiated (350cGy; 137Cs source, single 
dose) and transplanted with progeny of 50000 OAC1 or vehicle control treated CB CD34+ 
cells within 24h after irradiation. Peripheral bloods were collected at various time points by 
tail-vein bleeding. The blood samples were treated with RBC lysis buffer and then washed in 
PBS+1% BSA buffer before staining. Peripheral blood collected from untransplanted NSG 
mouse was used as a negative control. Mice were sacrificed 16 weeks after transplantation. 
For long-term engraftment assay, 2×106 BM cells from the primary recipient mice were 
infused into secondary recipient mice. These mice were also sacrificed 16 weeks after 
transplantation. BM cells were stained and analyzed by flow cytometry as described above.
Limiting dilution analysis
The frequency of human SRCs in uncultured CD34+ cells and the progeny of an equivalent 
number of CD34+ cells that were ex vivo expanded in the presence of vehicle control or 
OAC1 were analyzed by limiting dilution assay as reported by others4. Increasing doses of 
uncultured CD34+ cells (500, 2500, 5000) or the progeny of an equivalent number of CD34+ 
cells were infused into NSG mice. These mice were sacrificed 12 weeks after 
transplantation. The HSC frequency was calculated using L-Calc software (StemCell 
Technologies Inc.) and plotted using ELDA software (bioinf.wehi.edu.au/software/elda/).
siRNA-mediated knockdown analysis
CB CD34+ cells were transfected with 40nM OCT4 (sc-36123), HOXB4 (sc-38692) or 
scrambled siRNA (sc-37007) according to the manufacturer’s instructions (Santa cruz). 
OCT4 and HOXB4 protein expression levels were assessed following siRNA knockdown. 
Cells treated with siRNA were stained after 4 days of culture in the presence of vehicle 
control or OAC1, and analyzed by flow cytometry for HSC fraction.
In vivo teratoma formation assay
1×106 CD34+ cells from vehicle control cultures or cultures containing OAC1 or 1×106 
human H9 ES cells were subcutaneously injected into 6-week-old, Athymic nude mice16. 
The resulting teratomas were removed 6 weeks later. Samples from the teratomas were 
paraffin-embedded and serially sectioned using microtome (Leica Microsystems, Wetzlar, 
Germany). To analyze the three germ-layer lineage cells derived from injected H9 ES cells 
in the teratomas, sectioned slides were stained with hematoxylin and eosin (HE stain). 
Images were analyzed using an inverted microscope system (Nikon).
Statistical analysis
Results are expressed as mean values ± standard deviation. P value less than 0.05 (two tailed 
student t test) was considered as statistically significant.
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Results
OAC1 treatment results in increased numbers of phenotypic HSC and functional HPC
To test whether activation of OCT4 is involved in expansion of HSC, CD34+ cells from 
human cord blood were cultured for 4 days in medium containing 100 ng/mL of SCF, TPO 
and Flt3L with and without the OCT4 activator compound OAC110. A concentration of 
500nM OAC1, was the most effective for ex vivo HSC expansion (Supplementary Figure 
1A). The protein level of OCT4 expression greatly increased after culture of CB CD34+ cells 
with OAC1 (Figure 1a). Since OCT4, SOX2 and NANOG form an autoregulatory feedback 
loop, we also observed upregulation of SOX2 and NANOG in OAC1-treated cells 
(Supplementary Figures 2A and 2B). To assess whether OAC1 affects the epigenetic states 
in CD34+ cells, we examined the levels of Histone 3 lysine 4 trimethylation (H3K4me3) and 
Histone 3 lysine 9 trimethylation (H3K9me3) in OAC1-treated cells. H3K4me3 is known to 
be associated with transcriptional active state, while H3K9me3 has been well characterized 
as a mark of transcriptional inactive state17. The levels of H3K4me3 and H3K9me3 did not 
show significant difference in OAC1-treated cells (Supplementary Figures 2C and 2D), 
suggesting that OAC1 did not affect the epigenetic marks of these cells.
We firstly observed that numbers of CD34+CD38− cells significantly increased in the OAC1 
treated group after culture compared with the vehicle treated group (Figures 1b and c). We 
then carefully examined the effect of OAC1 in a more rigorously defined most primitive 
(Lin−CD34+CD38−CD45RA−CD90+CD49f+) HSC population18. We found that there was a 
7.6 fold increase in these cells in the OAC1 treated group compared with uncultured Day0 
group, and a 2.8 fold increase compared with vehicle treated group (Figures 1b and d). To 
further confirm the role of OCT4 during ex vivo HSC culture, we performed OCT4 
overexpression in CB CD34+ cells using lentiviral vectors and found that overexpression of 
OCT4 also resulted in significant increase in the number of phenotypic HSC compared to 
control vectors (Figure 1e). There was also a significant increase in phenotypic HSC for 7 
days in the presence of OAC1 (Supplementary Figure 3A). Also, the effect of OAC1 was 
reproducible when CB CD34+ cells were cultured in serum-free medium Stemline II 
(Supplementary Figure 3B). We also noticed that the number of phenotypically-defined 
endothelial progenitor cells (EPC, CD133+CD309+CD34+) significantly increased in the 
OAC1 treated group, while the number of mesenchymal stromal cells (MSC, 
CD45−CD73+CD105+CD90+) did not show significant differences in the OAC1 treated 
group (Supplementary Figure 3C and 3D). Therefore, our results suggest that OAC1 
facilitates cytokine stimulated ex vivo CB HSC expansion.
To assess whether OAC1 also enhanced cytokine stimulated ex vivo expansion of HPC, CB 
CD34+ cells treated with the cytokine combination with either OAC1 or vehicle control were 
seeded in semisolid methylcellulose culture medium and cultured for 14 days in the presence 
of a maximally stimulatory combination of cytokines (Erythropoietin, SCF, IL-3 and GM-
CSF). OAC1 significantly increased numbers of granulocyte/macrophage (CFU-GM), 
erythroid (BFU-E), and granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) 
progenitors after 4 days ex vivo culture (Figure 2a), demonstrating that OAC1 also enhances 
cytokine-stimulated ex vivo expansion of functionally recognizable HPC. To further confirm 
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that OAC1 enhances ex vivo expansion of HPC, suboptimal cytokine doses were either 
employed during ex vivo expansion (SCF, TPO and Flt3L), or during the CFU assay 
(Erythropoietin, SCF, IL-3 and GM-CSF). Significant increases in CFU numbers in OAC1 
treated group were observed in both situations (Figure 2b and 2c), suggesting that OAC1 
enhances ex vivo expansion of HPC with both full and suboptimal cytokine doses in the 
expansion and colony forming phases.
Culture of CB CD34+ with OAC1 enhances short and long-term engrafting HSC
The human cell immune-deficient mouse engraftment assay currently serves as the best 
model for determining functionality of human HSC19. To evaluate the functionality of 
OAC1-treated CD34+ cells, sublethally irradiated NSG mice were transplanted with the 
progeny of 50000 CB CD34+ cells that had been cultured for 4 days with SCF, TPO and 
Flt3L and with OAC1 or vehicle control. We observed significantly increased engraftment of 
OAC1 treated CB cells in primary recipients, compared to the vehicle control group (Figures 
3a and 3b), with across the board increase for human B cells, T cells and myeloid cells in the 
bone marrow (BM) of primary recipients (Figure 3c). To determine whether OAC1-
expanded cells had self-renewal capability, we transplanted BM cells from primary NSG 
mice 16 weeks after transplantation into secondary sublethally irradiated NSG mice. We 
found that the OAC1 expanded group also resulted in greater engraftment of human CD45+ 
cells in secondary mouse recipients (Figure 3d), suggesting that we had increased the long-
term engrafting capacity of self-renewing HSC after OAC1 treatment.
To assess the degree of HSC expansion by OAC1 treatment, we did a limiting dilution assay 
to compare the frequency of SRCs in Day 0 uncultured CD34+ cells, in the progeny of an 
equivalent number of cells in the presence of vehicle control, or OAC1 after 4 days ex vivo 
culture (Table 1). Poisson distribution analysis revealed an SRC frequency of 1/3723 in Day 
0 uncultured CD34+ cells, 1/6682 in vehicle control cultures and 1/1060 in cultures treated 
with OAC1 (Figure 4a). We calculated the presence of 269 SRCs in 1×106 Day 0 uncultured 
CD34+ cells, 150 SRCs and 943 SRCs in 1×106 cells from vehicle control and OAC1-treated 
cultures respectively (Table 2). So OAC1 treatment resulted in 3.5 fold increase in the 
number of SRCs compared with that in Day 0 uncultured CD34+ cells and 6.3 fold increase 
compared with that in cells treated with control vehicle (Figure 4b). Our data demonstrate 
that CB CD34+ cells cultured with OAC1 results in a significant expansion of SRC numbers.
HOXB4 is essential for OAC1-mediated expansion of cord blood HSC
HOXB4 is a homeobox transcriptional factor that appears to be an essential regulator of 
HSC self-renewal; overexpression of HOXB4 resulted in high-level ex vivo HSC 
expansion20, 21. Also, it has been reported that OCT4 could bind to the promoter region of 
HOXB4 at the site of 2952 bp from transcription start point7. So, we hypothesized that 
activation of OCT4 might work through upregulation of HOXB4 expression to ex vivo 
expand HSC. The expression level of HOXB4 in human CB CD34+ cells was assessed by 
flow cytometry after 4 days treatment with OAC1 or vehicle control. We observed that the 
expression of HOXB4 was significantly increased after culture of CB CD34+ cells with 
OAC1 compared to vehicle control (Figure 5a). To further confirm a functional link between 
upregulation of HOXB4 in OAC1-treated cells and the expansion of primitive HSC, we 
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transfected CD34+ cells with HOXB4 siRNA. siRNA-mediated HOXB4 knockdown led to a 
significant reduction in the absolute number of Lin−CD34+CD38−CD45RA−CD90+CD49f+ 
cells in OAC1-treated cells (Figure 5b), suggesting HOXB4 is essential for the generation of 
primitive HSC in OAC1-treated cells. Next, we asked whether OCT4 is required for the 
upregulation of HOXB4 in OAC1-treated cells by using OCT4 siRNA. Similar with HOXB4 
siRNA, knockdown of OCT4 led to a significant reduction in phenotypic HSC (Figure 5b). 
Furthermore, we found that siRNA mediated inhibition of OCT4 also resulted in marked 
reduction of HOXB4 expression in OAC1-treated cells (Figure 5c), while knockdown of 
HOXB4 did not affect the expression of OCT4 in OAC1-treated cells (Figure 5d), suggesting 
HOXB4 is downstream of OCT4 during ex vivo expansion of CB HSC.
Additionally, we tested whether knockdown of HOXB4 affects OAC1-mediated expansion 
of HPC. CB CD34+ cells were transfected with HOXB4 siRNA or OCT4 siRNA and then 
cultured with the cytokine combination with either OAC1 or vehicle control for 4 days. The 
treated cells were seeded in semisolid methylcellulose culture medium and cultured for 14 
days. We observed that knockdown of HOXB4 or OCT4 also blocked OAC1-mediated 
increased numbers of CFU-GM and CFU-GEMM colonies (Supplementary Figure 4A). To 
further demonstrate that OCT4 binds to the HOXB4 promoter region in HSC, we carried out 
a ChIP analysis using anti-OCT4 antibody. Consistently, we found that immunoprecipitation 
with OCT4 antibody showed marked enrichment for the −3000 bp of the HOXB4 promoter 
region (Supplementary Figure 4B). Taken together, our data indicate that OAC1 treatment 
leads to OCT4-mediated upregulation of HOXB4, which is essential for the generation of 
human CB Lin−CD34+CD38−CD45RA−CD90+CD49f+ HSC.
OAC1 treated CD34+ cells did not form teratoma in vivo
To exclude the possibility that the expanded cells contained leukemogenic potential, we 
followed the survival ratio of NSG mice transplanted with vehicle control or OAC1 treated 
CD34+ cells. Within the time frame of our experiments (up to 16 weeks post-transplant), 
there was no significant difference between vehicle control group and OAC1 treated group 
(Supplementary Figure 5, p>0.05), nor did we detect any evidence of the generation of 
leukemic cells, suggesting that OAC1 treatment did not cause malignant transformation of 
CD34+ cells during our observation periods.
Since OCT4 expression has been associated with induction of pluripotency that could 
potentially lead to the formation of teratomas, CD34+ cells from vehicle control cultures, 
OAC1 treatment cultures or human H9 ES cells were each injected subcutaneously into nude 
mice and were examined after 6 weeks. Teratomas, containing tissue from all three germ 
layers, formed from the H9 ES cells (Supplementary Figure 6) that were not observed in 
animals injected with CD34+ cells from vehicle control cultures or OAC1 treatment cultures.
Discussion
Understanding the regulation of HSC by intrinsic and extrinsic factors is important for 
improving HCT. Although many extrinsic factors have been identified as regulators of HSC, 
such as cytokines22, Notch ligands23, Wnt ligands24, and Angiopoietins25, to the best of our 
knowledge, HOXB4 is the only intrinsic factor that shows positive effects on ex vivo HSC 
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expansion. Here we demonstrate that OCT4 is another intrinsic factor that plays an 
important role in HSC expansion. By utilization of OAC1, we observed significant increase 
in the number of phenotypic HSC, HPC, and short-term and long-term HSC in vivo 
repopulating capability.
We used a simple HSC culture medium containing SCF, TPO and Flt3L, with or without 
serum, and in this system we observed OCT4-mediated HSC expansion in 4 days. The 
quality of the OAC1-expanded HSC did not appear to be impaired, as they showed 
multilineage repopulating capability. Besides, all NSG mice transplanted with OAC1-
expanded cells remained healthy and without any obvious disorders. Our study also followed 
engraftment in secondary transplanted animals for 4 months after 4-months engraftment in 
primary mice, suggesting that the enhancement was for long-term repopulating, self-
renewing HSC. While we did not detect any leukemic transformation of cells engrafted with 
ex-vivo cultured CD34+ CB cells for up to 16 weeks, and did not detect any teratoma 
formation by these cultured cells when injected into mice, we can not completely rule out 
the possibility that the ex vivo expanded cells contained leukemogenic potential. This is 
always the concern for all the ex vivo modified cells regardless of how they are expanded. 
Future studies on non human primates and humans may be needed before full clinical safety 
is known.
How physiological HSC self-renewal is regulated remains incompletely understood. Our 
data showed, for the first time, that overexpression of OCT4 enhanced ex vivo HSC 
expansion and suggest that OCT4 plays an essential role in HSC self-renewal. Direct 
generation of progenitors of hematopoietic fate from human dermal fibroblasts by ectopic 
expression of OCT4 has recently been reported9, and this finding reinforces our current 
study, that indicates OCT4 as a component in HSC biology. OCT4 expression in somatic 
stem cells has been described11–13, however, the links to functional activities are largely 
missing. Previously, it was reported that Oct4 gene ablation in mice did not show significant 
difference in various tissues, including intestine, bone marrow and brain26. However, these 
results could be explained by the functional redundancy within the Oct family and Pou 
domain family and could not rule out the possibility that overexpression of Oct4 would have 
impact in these tissues. Recent reports also showed that overexpression of OCT4 increased 
the proliferative capacity and functionality of mesenchymal stem cells27, 28. Our data 
indicate activation of OCT4 by OAC1 or lentiviral vector is sufficient to enhance HSC 
expansion while preserving the functionality. This information raises a number of important 
possibilities regarding the function of OCT4 in other types of somatic stem cells.
The human homeodomain containing transcription factor HOXB4 was the first gene shown 
to dramatically expand murine HSC when ectopically expressed20. Ectopic expression of 
HOXB4 also enhanced the generation of definitive HSC from murine ES cells29. TAT-
HOXB4 and degradation-resistant HOXB4 variant also markedly enhanced ex vivo 
expansion of human HSC21, 30. These studies demonstrated that the function of HOXB4 is 
important for HSC. We found that the expression of HOXB4 protein was largely increased in 
OAC1-treated CD34+ cells, and knockdown of HOXB4 blocked the ex vivo expansion of 
CB HSC by OAC1, suggesting HOXB4 as a key component in mediating OCT4 function in 
ex vivo HSC expansion.
Huang et al. Page 8
Leukemia. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
As reported, detection of OCT4 expression by RT-PCR could be misled by pseudogene 
transcripts31, so we examined the protein expression level of OCT4 in CB CD34+ cells and 
showed that significant elevation of OCT4 protein expression was observed in CB CD34+ 
cells treated with OAC1. Recently, it was reported that valproic acid treatment also led to 
upregulation of OCT4, SOX2 and NANOG, which is essential for the valproic acid-
mediated expansion of cord blood stem cells32. In our study, we emphasized that the 
function of OCT4 was crucial during ex vivo CB HSC expansion and demonstrated that 
HOXB4 was a important downstream target in mediating ex vivo HSC expansion by OCT4.
In summary, overexpression of OCT4 by OAC1 regulates ex vivo HSC expansion by 
regulating HOXB4 expression, the data presented here suggest the importance of OCT4 in 
HSC function. It would be interesting to explore the potential of OAC1 treatment for 
translation to clinical HSC transplantation and to search for better structural analogs of 
OAC1 that will be more effective in enhancing ex vivo HSC expansion. The approach used 
in our report may have the potential to generate sufficient numbers of in vivo repopulating 
HSC to facilitate allogeneic CB HCT.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Culture of human CB CD34+ cells with OAC1 resulted in expansion of phenotypic HSC. (a) 
Expression of OCT4 in cultured CB CD34+ cells in the presence of vehicle control or 
OAC1. Left are the representative plots of OCT4 expression in vehicle control and OAC1 
treated cells. Right is the quantification of the percentage of cells showing OCT4 expression. 
Negative control indicates OCT4 expression in MRC-5 fibroblast cells, positive control 
indicates OCT4 expression in H9 embryonic stem cells. n=4, ** indicates p<0.01. (b) 
Representative contour plots of Day 4 expansion of CB CD34+ cells with OAC1 or vehicle 
control. (c) The number of CD34+CD38− cells significantly increased in OAC1-treated 
group compared to vehicle-treated group at Day 4. n=7, ** indicates p<0.01. (d) The number 
of Lin−CD34+CD38−CD45RA−CD90+CD49f+ cells significantly increased in OAC1-treated 
group compared to vehicle-treated group at Day 4. n=7, ** indicates p<0.01. (e) CB CD34+ 
cells were transduced with lentiviral vector pCSC-GW and pCSC-OCT4 as described in 
Materials and Methods section, the number of HSC (CD34+CD38−CD45RA−CD90+CD49f+ 
cells)/106 total cells were calculated by using flow cytometry. n=3, * indicates p<0.05. Data 
represent the mean ± s.d.
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Figure 2. 
Culture of CB CD34+ cells with OAC1 resulted in increased number of CFUs. (a) CFU 
numbers in 1000 cells of Day 0 uncultured CD34+ cells and the progeny of an equivalent 
number of CD34+ cells that were expanded in the presence of vehicle control or OAC1 for 4 
days. n=3, * indicates p<0.05, ** indicates p<0.01. (b) CFU numbers in the progeny of 1000 
CD34+ cells that were expanded in the presence of vehicle control or OAC1 for 4 days with 
different doses of cytokines. Full dose: 100ng/mL SCF, 100ng/mL TPO and 100ng/mL 
Flt3L; 1/2 dose: 50ng/mL SCF, 50ng/mL TPO and 50ng/mL Flt3L; 1/4 dose: 25ng/mL SCF, 
25ng/mL TPO and 25ng/mL Flt3L; 1/8 dose: 12.5ng/mL SCF, 12.5ng/mL TPO and 
12.5ng/mL Flt3L. * indicates p<0.05, ** indicates p<0.01, N.S. indicates p>0.05. (c) CFU 
numbers in the progeny of 1000 CD34+ cells that were expanded in the presence of vehicle 
control or OAC1 for 4 days and different doses of cytokines were only employed during 
CFU assay. Full dose: 1 U/mL erythropoietin, 50 ng/mL SCF, 10 ng/mL IL-3, and 10 ng/mL 
GM-CSF; 1/2 dose: 0.5 U/mL erythropoietin, 25 ng/mL SCF, 5 ng/mL IL-3, and 5 ng/mL 
GM-CSF; 1/4 dose: 0.25 U/mL erythropoietin, 12.5 ng/mL SCF, 2.5 ng/mL IL-3, and 2.5 
ng/mL GM-CSF; 1/8 dose: 0.125 U/mL erythropoietin, 6.25 ng/mL SCF, 1.25 ng/mL IL-3, 
and 1.25 ng/mL GM-CSF. * indicates p<0.05, ** indicates p<0.01, N.S. indicates p>0.05. 
Data represent the mean ± s.d.
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Figure 3. 
Effect of OAC1 treatment on human CB CD34+ engraftment of NSG mice. NSG mice were 
transplanted with progeny of 50000 OAC1 or vehicle control treated cells after sublethally 
irradiation. (a) Representative flow cytometric analysis of human engraftment in the bone 
marrow (BM) of NSG mice, 16 weeks after transplant. Left is from a mouse without 
transplantation (negative control), center and right are from mice transplanted with human 
CB CD34+ cells cultured with vehicle control or OAC1 for 4 days. Human engraftment was 
assessed as the percentage of human CD45+ cells. (b) Peripheral blood (PB) was collected at 
different time points after transplantation and cells were stained for human CD45 
percentage. Data are pooled from two independent experiments (n=6-8 mice for each group). 
* indicates p<0.05, ** indicates p<0.01. (c) T cell (CD3+), B cell (CD19+) and myeloid cell 
(CD33+) chimerism in primary NSG mice bone marrow. Data are pooled from two 
independent experiments (n=6-8 mice for each group). * indicates p<0.05, ** indicates 
p<0.01. (d) Human CD45 cell chimerism in the PB and BM from secondary recipient NSG 
mice (n=5 mice for each group). ** indicates p<0.01. Data represent the mean ± s.d.
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Figure 4. 
The frequency of human SRCs in uncultured CD34+ cells and the progeny of the equivalent 
number of cells treated with vehicle control or OAC1. (a) Poisson statistical analysis of data 
from Table 1. Shapes represent the percentage of negative mice for each dose of cells. Solid 
lines indicate the best-fit linear model for each data set. Dotted lines represent 95% 
confidence intervals. (b) The number of SRCs in 1×106 CD34+ cells. * indicates p<0.05, ** 
indicates p<0.01. Data represent the mean ± s.e.
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Figure 5. 
HOXB4 mediates the effect of OAC1 on ex vivo expansion of HSC. (a) Expression of 
HOXB4 in the progeny of CD34+ cells after 4 days culture in the presence of vehicle control 
or OAC1. Left are the representative plots of HOXB4 expression in vehicle control and 
OAC1 treated cells. Right is the quantification of the percentage of cells showing HOXB4 
expression. n=3, ** indicates p<0.01. (b) CB CD34+ cells were transfected with HOXB4, 
OCT4 or scrambled (negative control) siRNA as described in Materials and Methods 
section, the number of HSC (Lin−CD34+CD38−CD45RA−CD90+CD49f+ cells)/106 total 
cells were calculated by using flow cytometry. n=3, N.S. indicates p>0.05, ** indicates 
p<0.01. (c) HOXB4 expression was analyzed by flow cytometry after transfection with 
HOXB4, OCT4 or scrambled siRNA and cultured for 4 days in the presence of vehicle 
control or OAC1. n=3, ** indicates p<0.01. (d) OCT4 expression was analyzed by flow 
cytometry after transfection with HOXB4, OCT4 or scrambled siRNA and cultured for 4 
days in the presence of vehicle control or OAC1. n=3, N.S. indicates p>0.05, ** indicates 
p<0.01. Data represent the mean ± s.d.
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Table 1
SRC frequency determined by limiting dilution assay in NSG mice
Culture conditions Cells transplanted Number of mice with > 1% human cell 
chimerism/total number of mice
Day 0 Uncultured
500 1/4
2500 2/5
5000 3/4
Vehicle control
Number of CD34+ cells at 
starting
Number of cells transplanted
500 3.5×103±0.8×102 0/5
2500 1.8×104±3.8×102 2/5
5000 3.5×104±7.5×102 2/4
OAC1
500 3.6×103±1.2×102 3/5
2500 1.8×104±6.0×102 3/4
5000 3.6×104±1.2×103 5/5
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